Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 110.00
Bid: 110.00
Ask: 110.20
Change: -0.60 (-0.54%)
Spread: 0.20 (0.182%)
Open: 110.20
High: 110.80
Low: 110.00
Prev. Close: 110.60
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Omicron hope lifts FTSE despite UK virus surge

Wed, 22nd Dec 2021 17:03

(Alliance News) - Equity prices in London on Wednesday shook off news of fresh daily record coronavirus infections in the UK to end higher amid cautious optimism over the severity of the Omicron variant.

The FTSE 100 index closed up 44.25 points, or 0.6%, at 7,341.66. The FTSE 250 ended up 260.49 points, or 1.1%, at 23,080.79, and the AIM All-Share closed up 10.24 points, or 0.9%, at 1,183.81.

The Cboe UK 100 ended up 0.5% at 726.92, the Cboe UK 250 closed up 1.3% at 20478.57, and the Cboe Small Companies ended up 1.2% at 15004.11.

In European equities on Wednesday, the CAC 40 in Paris ended up 1.1% and the DAX 40 in Frankfurt ended up 1.0%.

Tentative optimism over the Omicron coronavirus variant supported markets on Wednesday.

"Some preliminary results from the UK Health & Security agency around the effects of the Omicron variant appear to be being received positively today. In line with South Africa's experience, it would appear that the Omicron variant does indeed appear to be milder, although the report also suggests that the higher infection rate could also place increased strain on hospitals, if enough people get it even if mortality is lower," said Michael Hewson, chief market analyst at CMC Markets.

"Nonetheless, it is still good news, and helps justify the move to delay a decision on new restrictions in England until after Christmas, and potentially allow greater leeway next week when restrictions could well change again."

UK Prime Minister Boris Johnson on Tuesday gave the go-ahead for people's Christmas plans, although he warned tougher restrictions could be implemented post-December 25.

However, Wales on Wednesday followed Scotland in unveiling new post-Christmas coronavirus curbs, primarily around hospitality and large events, as the UK's devolved nations move at different speeds to surging Omicron variant cases.

This came as the UK clocked another daily new cases record – 106,122 – as it announced it would buy millions of Covid pills, and also cut the isolation period for infected people from 10 to seven days with negative tests.

Sterling strengthened, however. The pound was quoted at USD1.3346 at the London equities close Wednesday, jumping from USD1.3248 at the close on Tuesday after some mixed gross domestic product data.

On the quarter before, UK gross domestic product advanced by 1.1% in the three months to September, slower than a 5.4% rise in the three months to July and missing consensus of an expansion of 1.3%, which would have matched the first estimate. On a year before, the UK economy grew by 6.8% in the third quarter, slightly beating the market forecast of 6.6% annual growth, which also would have matched the first estimate.

The ONS said the largest contributors to the increase in GDP were hospitality and arts, entertainment & recreation, following the further easing of restrictions and reopening of the economy during the period - something which could now be at risk given the Omicron wave.

Other countries have started to impose restrictions to curb the virus's spread. The Netherlands has already imposed a Christmas lockdown and Germany has slapped a limit of 10 people on private parties, closed nightclubs and banned spectators from major events including soccer matches.

Shaking this off, London-listed travel and leisure firms gained on Wednesday. Jet engine maker Rolls-Royce ended up 3.3% and Holiday Inn owner InterContinental Hotels Group rose 2.7%.

Pandemic-battered stocks also ended in the green in the mid-cap FTSE 250 index, with food and beverage outlets operator SSP Group rising 4.8% and Mitchells & Butlers up 2.7%.

Elsewhere, Taylor Wimpey rose 2.2% after committing to removing terms from contracts that double ground rents for leaseholders every 10 years.

Taylor Wimpey said the UK Competition & Markets Authority investigation into the historical sale of leasehold properties with doubling ground rent clauses by the company is closed, following the agreement of voluntary undertakings. The High Wycombe-based housebuilder said the cost of the undertakings falls within the original provision Taylor Wimpey made in 2017.

Syncona jumped 5.5% after the healthcare investor said its portfolio company Gyroscope Therapeutics will be sold to Swiss pharmaceutical maker Novartis for up to USD1.5 billion.

Syncona has a 54% stake in Gyroscope following a USD42 million investment in March, after co-founding the business in 2016. In a bumper payday, Syncona will receive upfront cash proceeds of GBP334 million from the deal, representing a GBP180 million uplift to the current holding value.

Stocks in New York were higher at the London equities close, with the DJIA up 0.5%, the S&P 500 index up 0.7%, and the Nasdaq Composite up 0.9%.

The dollar was on the back foot amid Wednesday's cautious optimism, failing to get a boost from an upwards revision to the US economy's performance in the third quarter.

On an annual basis, the US economy grew at a rate of 2.3% in the three months to September, slowing from a 6.7% expansion in the second quarter. The latest reading beat the market forecast of an expansion of 2.1%, however, which would have matched the second estimate.

The euro stood at USD1.1327 at the European equities close Wednesday, up against USD1.1267 at the same time on Tuesday.

Gold benefited from dollar weakness. The shining metal was quoted at USD1,797.90 an ounce at the London equities close Wednesday, rising from USD1,785.40 at the close on Tuesday.

However, the safe haven Japanese yen eased back. Against the yen, the dollar rose to JPY114.22 compared to JPY114.14 late Tuesday.

Brent oil was quoted at USD74.74 a barrel at the London equities close Wednesday, up from USD73.48 late Tuesday.

Thursday's economic calendar has German import prices at 0700 GMT and US initial jobless claims at 1330 GMT, alongside durable goods orders and core personal consumption expenditures due at the same time.

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
7 Feb 2023 09:45

Syncona net asset value falls on "challenging" market, dollar weakness

(Alliance News) - Syncona Ltd on Tuesday reported a decline in its third quarter net asset value, noting a depreciating US dollar against sterling and a decline in the share price of investees.

Read more
7 Feb 2023 07:16

Syncona NAV falls in Q3

(Sharecast News) - Healthcare company Syncona said on Tuesday that net assets had fallen in the three months ended 31 December, principally due to the declining value of its quoted holdings and foreign exchange fluctuations.

Read more
25 Jan 2023 12:14

Life Science REIT lets second floor of Rolling Stock Yard in London

(Alliance News) - Life Science REIT PLC on Wednesday said it signed an agreement to lease the second floor of its Rolling Stock Yard asset near King's Cross, London, to a life science company backed by Syncona Ltd.

Read more
22 Dec 2022 08:04

Syncona investee Autolus sells more American shares

(Sharecast News) - Life science-focussed healthcare company Syncona said on Thursday that its portfolio company Autolus Therapeutics had announced that the underwriters of its public offering of American depositary shares (ADSs), which closed on 13 December, had partially exercised their option to purchase an additional 6,927,102 ADSs.

Read more
9 Dec 2022 10:36

Syncona portfolio firm hits 70% remission rate goal in leukaemia trial

(Alliance News) - Syncona Ltd on Friday said portfolio company Autolus Therapeutics PLC achieved the primary endpoint in the clinical trial of its treatment for acute lymphoblastic leukaemia.

Read more
9 Dec 2022 07:21

Syncona's Autolus leukemia treatment meets trial endpoint

(Sharecast News) - Syncona portfolio company Autolus Therapeutics announced that a phase 2 clinical trial in adult acute lymphoblastic leukemia (ALL) patients has met its primary endpoint at interim analysis.

Read more
6 Dec 2022 12:00

Syncona investee Achilles continues to progress cancer trials

(Alliance News) - Syncona Ltd on Tuesday noted the continued positive progress in lung cancer trials by its portfolio company.

Read more
1 Dec 2022 10:16

Syncona's Achilles says cancer treatment shows promise; seals buy

(Alliance News) - Syncona Ltd on Thursday noted a promising safety profile for a cancer therapy concocted by one investee, and separately announced the completion of an acquisition in the retinal gene therapy space.

Read more
29 Nov 2022 09:05

TOP NEWS: AstraZeneca to buy Neogene for cancer treatment

(Alliance News) - AstraZeneca PLC said it agreed to buy Neogene Therapeutics Inc for the treatment of cancer, as also noted by healthcare company Syncona Ltd on Tuesday.

Read more
29 Nov 2022 08:57

LONDON MARKET OPEN: Stocks up as protests in China deterred by police

(Alliance News) - The FSTE 100 opened in the green on Tuesday as investors were reassured that civil unrest in China would be short lived amid unyielding action by the authorities.

Read more
29 Nov 2022 07:50

LONDON BRIEFING: easyJet boasts "record bounce back" as loss narrows

(Alliance News) - Stocks in London were set to open slightly higher on Tuesday as unrest in the world's second largest economy continued.

Read more
17 Nov 2022 10:53

Syncona net assets rise in half year and outlines 10-year growth plans

(Alliance News) - Syncona Ltd on Thursday said net assets increased in the first half of its financial year, as it outlined plans to grow its net assets to GBP5 billion within the next 10 years.

Read more
17 Nov 2022 08:16

Syncona makes 'positive' operational and clinical progress in H1

(Sharecast News) - Healthcare company Syncona said on Thursday that it had delivered "positive operational and clinical progress" across its portfolio against a challenging macro backdrop in the six months ended 30 September.

Read more
15 Nov 2022 14:41

IN BRIEF: Syncona notes investee Freeline's third-quarter loss narrows

Syncona Ltd - London-based investor in healthcare companies - Notes third-quarter results of investee Freeline Therapeutics Holdings PLC. Freeline's pretax loss in the third quarter that ended September 30 narrows to USD65.9 million from USD105.7 million a year prior. Research & development expenses decrease to USD53.6 million from USD70.8 million, and total operating expenses fall by 27% to USD78.6 million from USD108.0 million. Freeline continues to make no revenue. Freeline enters a definitive agreement to sell its chemistry, manufacturing & control focused German subsidiary and related intellectual property for USD25 million, with the sale being subject to price adjustments.

Read more
10 Nov 2022 21:19

TRADING UPDATES: Zambeef expects profit jump; Mobile Streams wins deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.